


Cardiovascular Health

Controlling Both HDL And LDL is Important

Reducing the Risk of Coronary Heart Disease



Framingham Study; Am J Cardiol 2000.

Torcetrapib

CETP Inhibitor – Tablet

◆ **Target Indication and Phase 3 Timing**

- **Adjunctive Therapy with HMG-CoA Reductase Inhibitors or Ezetimibe for Treatment of Primary Hypercholesterolemia (Heterozygous Familial and Nonfamilial) or Mixed Dyslipidemia.**
- **Phase 3 Start: November 2007**

◆ **Regulatory Status**

- **FDA Has Endorsed The Plan**

Second-Generation CETP Inhibitors

◆ Two Agents Rapidly Moving Through Development


- **CP-800,569: Novel Structural Class, Phase 1 Complete**
- **PF-3,185,043: Torcetrapib Analog in Phase 1**

◆ Neither Elevates Blood Pressure in Preclinical Models

CP-800,569

Phase 1 Multiple Dose HDL


- ◆ Pioneering NADDS (Nanoadsorbate Drug Delivery System) to Enable Phase 1 Clinical Studies
- ◆ FIH Single Dose Study – Linear PK/Exposure from 30mg to 1100mg
- ◆ 14 Day Multiple Dose in Healthy Volunteers – Safe & Well Tolerated, No BP Changes



CP-800,569

Phase 1 Multiple Dose LDL

*A7291003, 1100 mg Multidose, Treated vs. Placebo Subjects:
Changes in Plasma LDL-C (Friedewald Calculated)*



Driving New Science To Discover Valued Medicines

Compound

Mechanism

Disease

Torcetrapib

CETP Inhibition

Atherosclerosis

Maraviroc

CCR-5 Inhibition

AIDS

CP-690,550

Janus Kinase3 Inhibition

Rheumatoid Arthritis

Sutent, Axitinib

Tyrosine Kinase Inhibition

Cancer

Lyrica

Alpha 2 Delta Blockade

Epilepsy, Neuropathic Pain

Chantix

Nicotine Partial Agonism

Smoking Addiction


Changing How We Work

The Challenge


- ◆ **More Candidates**
- ◆ **Better Candidates – Less Attrition in Early Development**
- ◆ **Enhanced Productivity**
- ◆ **Broaden Our Scope Through External Collaborations**
- ◆ **Sharper Focus on Major Medical and Commercial Opportunities**

More and Better Candidates

New Molecular Entities



Early Candidate Attrition



* Projected as of 1/07

Enhanced Productivity

◆ Discovery Research

- Creation of Centers of Emphasis for Key Technologies
- Non-Core Work Being Done in Low-Cost Environments

◆ Clinical Research

- Adaptive Clinical Designs
- Using Low-Cost, High-Quality Clinical Centers

◆ Infrastructure Improvement

- Reduction of Capital Budget by >60% Since 2002
- Standardizations in it Resulting in 25% Cost Improvement with More Funding Allocated to New Application Design

Pharmaceutical Sciences Reorganization

Doing More With Less

	July 2002	July 2006
Colleagues	3,800	2,668
Annual Budget	>\$1B	\$0.8B
Pipeline		
New Molecular Entities	94	153
Product Enhancements	71	77

Managing the Entire Life Cycle

Therapeutic Areas

Allergy and Respiratory

Cardiovascular, Metabolic and Endocrine

Dermatology

Gastrointestinal / Liver Disease

Genitourinary

Infectious Diseases

Inflammation

Neurosciences


Oncology

Ophthalmology

Pain

Therapeutic Area Strategy

- ◆ **Unified View of the Future Patient and Environment**
- ◆ **Common Definition of Success**
 - Product Concepts
 - Enabling Strategies
- ◆ **Commitment to a Seamless Research, Development, and Commercialization Continuum**



What's Different In Philosophy?

A Call to the Scientists Around the World

- ***We Want to Collaborate With You***
- ***We Want You to Bring Us Your Ideas and Suggestions***
- ***We Want Your Advice***

What's Different In Philosophy?

External Collaborations



Bend Research



TransTech

Pfizer External Research Network

“The Incubator”

Purpose:

- ◆ **To Gain Rapid, Broader Access to Science Underlying Disease and to Enabling Technologies**

Site:

- ◆ **Pfizer La Jolla Campus**
- ◆ **Will House 3-7 Unique “Start-Ups”**
- ◆ **Will Prove Infrastructure and Support**

Function:

- ◆ **Small Teams Working to Provide Scientific Concepts**
- ◆ **Work on Problems Central to the PGRD Portfolio**
- ◆ **Once Concept is Proven, Continue as Either Pfizer-Associated or Independent Businesses**

A Bright Future

- ◆ **Real Momentum**
- ◆ **Aggressive Targets**
- ◆ **World-Class Science**
- ◆ **Will to Win**

Today's R&D Agenda

- ◆ **Cardiovascular** (*Steve Ryder*)
- ◆ **Oncology** (*Declan Doogan*)
- ◆ **Neurosciences** (*Martin Mackay*)

Lunch

- ◆ **Infectious Diseases** (*Ethan Weiner*)
- ◆ **Research Platforms** (*Martin Mackay*)
- ◆ **R&D Closing Remarks** (*John LaMattina*)
- ◆ **Business Transformation / External Sourcing**
(*David Shedlarz / Ed Harrigan*)

Break

- ◆ **Q & A**
- ◆ **Closing** (*Jeff Kindler*)